BioLineRx Licenses Technology to Ayrmid Pharma
Ticker: BLRX · Form: 6-K · Filed: Nov 21, 2024 · CIK: 1498403
Sentiment: neutral
Topics: licensing-agreement, commercialization, royalty
TL;DR
BioLineRx inks a licensing deal with Ayrmid Pharma for its tech, royalty payments expected.
AI Summary
On November 20, 2024, BioLineRx Ltd. entered into a license agreement with Ayrmid Pharma Ltd. This agreement grants Ayrmid Pharma an exclusive, transferable, and royalty-bearing license. The specific terms and financial details of this license are not fully disclosed in this filing.
Why It Matters
This licensing deal could represent a new revenue stream for BioLineRx and signifies progress in commercializing its technology.
Risk Assessment
Risk Level: medium — The nature of licensing agreements and the early stage of commercialization can introduce uncertainty regarding future revenue and market success.
Key Players & Entities
- BioLineRx Ltd. (company) — Licensor
- Ayrmid Pharma Ltd. (company) — Licensee
- November 20, 2024 (date) — Date of License Agreement
FAQ
What specific technology or product is being licensed by BioLineRx to Ayrmid Pharma?
The filing does not specify the exact technology or product being licensed, only that a license agreement was entered into.
What are the royalty rates and payment terms in the license agreement?
The filing states the license is royalty-bearing but does not disclose the specific royalty rates or payment terms.
What is the geographic scope of the license granted to Ayrmid Pharma?
The filing does not specify the geographic territory covered by the license agreement.
Are there any milestones or performance obligations for Ayrmid Pharma under the agreement?
The filing mentions the license is exclusive, transferable, and royalty-bearing, but does not detail specific milestones or performance obligations.
What is the duration of the license agreement?
The filing does not state the term or duration of the license agreement.
Filing Stats: 2,609 words · 10 min read · ~9 pages · Grade level 13.9 · Accepted 2024-11-21 06:50:23
Key Financial Figures
- $10 million — see is required to pay a non-refundable $10 million upfront payment within ten days of the
- $87 million — . The Company is also entitled to up to $87 million of certain commercial and sales milesto
- $16.5 m — Company will make aggregate payments of $16.5 million, as partial repayment of the loan
- $4 million — the Loan Agreement has been reduced to $4 million. All other terms of the Loan Agreement
- $2 million — the Company agreed to pay MTS a fee of $2 million. Registered Direct Offering On Novemb
- $0.5464 — ants"), at a combined purchase price of $0.5464 per ADS and accompanying Ordinary Warra
- $0.5463 — S and accompanying Ordinary Warrant and $0.5463 per Pre-Funded Warrant and accompanying
- $9.0 million — ercises of Warrants) are expected to be $9.0 million. The Offering is expected to close on o
- $0.0001 — ely exercisable at an exercise price of $0.0001 per ADS, subject to adjustment as set f
- $0.5900 — nary Warrants have an exercise price of $0.5900 per ADS, subject to adjustment as set f
- $0.6557 — he Nasdaq Stock Market equal or exceeds $0.6557 (subject to certain adjustments) for an
- $20 m — erm bank deposits will be approximately $20 million, excluding any royalty fees or pa
- $17.2 m — d September 30, 2024 were approximately $17.2 million, including $4.5 million of net pr
- $4.5 million — approximately $17.2 million, including $4.5 million of net product sales from Aphexda. The
- $10 m — ent under the License Agreement will be $10 million, the Closing Date of the Offering
Filing Documents
- zk2432369.htm (6-K) — 40KB
- exhibit_5-1.htm (EX-5.1) — 11KB
- exhibit_5-2.htm (EX-5.2) — 15KB
- exhibit_10-1.htm (EX-10.1) — 325KB
- exhibit_10-2.htm (EX-10.2) — 74KB
- exhibit_10-3.htm (EX-10.3) — 191KB
- exhibit_10-4.htm (EX-10.4) — 82KB
- exhibit_10-5.htm (EX-10.5) — 87KB
- exhibit_99-1.htm (EX-99.1) — 24KB
- image0.jpg (GRAPHIC) — 24KB
- image1.jpg (GRAPHIC) — 9KB
- image00002.jpg (GRAPHIC) — 9KB
- image00003.jpg (GRAPHIC) — 7KB
- image00005.jpg (GRAPHIC) — 3KB
- 0001178913-24-003792.txt ( ) — 923KB
Forward Looking Statements
Forward Looking Statements This Report on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon the Company's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company's control. For example, forward looking statements in this Report on Form 6-K include that the upfront payment under the License Agreement will be $10 million, the Closing Date of the Offering is expected to be on or about November 21, 2024, the expected gross proceeds from the Offering is $9.0 million, the Company's expected use of the net proceeds from the Offering will be for general corporate purposes and to advance its pancreatic program as well as pipeline expansion and that the Company's undertaking of certain cost-cutting and workforce reduction measures is expected to reduce the Company's annual cash burn, effective January 1, 2025, by approximately 70%. In fact, the closing of the Offering and the effectiveness of the Amendment are subject to the satisfaction of certain conditions. If these conditions are not satisfied, then the Company may never receive the proceeds from the sale of the securities in the Offering. In addition, the Company's expected use of net proceeds from the Offering represents its current intentions based on its present plans and business condition, which could change in the future as its plans and business conditions evolve. For this reason, among others, you should not place undue reliance upon the Company's forward-looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking Attached hereto are